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E-mail address: susana.novella@uv.es (S. Novella).Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase. ADMA
accumulation, mainly due to a decreased dimethylarginine dimethylaminohydrolase (DDAH) activity,
has been related to the development of cardiovascular diseases. We investigate whether estradiol pre-
vents the changes induced by oxidized low density lipoprotein (oxLDL) on the DDAH/ADMA/NO pathway
in human umbilical artery endothelial cells (HUAEC). HUAEC were exposed to estradiol, native LDL
(nLDL), oxLDL and their combinations for 24 h. In some experiments, cells were also exposed to the
unspeciﬁc estrogen receptor (ER) antagonist ICI 182780, the speciﬁc ERa antagonist MPP or speciﬁc ago-
nists for ERa, ERb and GPER. ADMA concentration was measured by HPLC and concentration of NO by
amperometry. Protein expression and DDAH activity were measured by immunoblotting and an enzy-
matic method, respectively. oxLDL, but not nLDL, increased ADMA concentration with a concomitant
decrease on DDAH activity. oxLDL reduced eNOS protein and NO production. Estradiol alone had no
effects on DDAH/ADMA/NO pathway, but increased the attenuated endothelial NO production induced
by oxLDL by reduction in ADMA and preventing loss of eNOS protein levels. ICI 182780 and MPP com-
pletely abolished these effects of estradiol on oxLDL-exposed cells. ERa agonist, but not ERb and GPER
agonists, mirrored estradiol effects on NO production. In conclusion, estradiol restores (1) DDAH activity,
and therefore ADMA levels, and (2) NO production impaired by oxLDL in HUAEC acting through ERa.
 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Nitric oxide (NO) plays an essential role as mediator in the car-
diovascular system and its release protects the vasculature against
vascular diseases (Vanhoutte et al., 2009). NO is mainly produced
by endothelial NO synthase (eNOS) and endothelial dysfunction
is characterized by a loss of NO bioavailability. Impairment of eNOS
activity by endogenous inhibitors such as asymmetrical dimethyl-
arginine (ADMA) in endothelial dysfunction-associated diseases
has gained interest (Leiper et al., 2007).
ADMA exerts its biological effects by competitively inhibiting
NO synthesis and thus modulating the vascular response, and
elevated levels of ADMA have been reported in many conditions
associated with a high cardiovascular risk. ADMA is a metabolicd Ltd. All rights reserved.
– INCLIVA, Hospital Clínico
0 Valencia, Spain. Tel.: +34 96by-product of continuous protein turnover in cells, formed during
proteolysis of methylated proteins, which is catalyzed by S-adeno-
sylmethionine protein N-methyltransferase I (PRMT-1). Most of
ADMA is metabolized to citrulline and dimethylamine through
the activity of two isoforms of dimethylarginine dimethylami-
nohydrolase (DDAH) (Pope et al., 2009). DDAH-I is associated with
tissues that express high levels of neuronal nitric oxide synthase
(nNOS), whereas DDAH-II is thought to be associated with tissues
that express eNOS (Leiper and Vallance, 1999). However, the bio-
chemical properties and the contribution of each enzyme to the
regulation of endothelial NO production have yet to be elucidated
(Pope et al., 2009).
Oxidized low-density lipoprotein (oxLDL) acts as a risk marker
for human cardiovascular disease and as an etiological factor in
the pathogenesis of atherosclerosis (Steinberg, 2009). In conditions
of oxidative stress, oxLDL results from oxidation of low-density
lipoprotein (LDL) at the vascular wall and can cause endothelial
dysfunction (Davignon and Ganz, 2004). Endothelial cells exposed
to oxLDL showed many signs of dysfunction or injury, such as
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migration, induction of apoptosis and increased vessel stiffness
which cause morphological changes (Vanhoutte et al., 2009).
The increase of ADMA level in patients and animals with hyper-
cholesterolemia and in endothelial cells treated with oxLDL has
been related to an increase of ADMA concentration as a conse-
quence of a decreased DDAH activity, induced by oxidative stress
and/or inﬂammatory factors (Ito et al., 1999; Boger et al., 2000).
Clinical and experimental studies have highlighted the role of
estrogens in many physiological processes, among them the car-
diovascular system. Indeed, experimental evidence suggest that
estrogen, particularly the endogenous 17b-estradiol, exerts cardio-
vascular protection via the promotion of endothelial vasodilator
synthesis, including NO production through both increased expres-
sion and activity of eNOS (Mendelsohn, 2009) and prostacyclin
(Sobrino et al., 2010) as well as through a reduction in endothelial
production of ADMA (Holden et al., 2003; Monsalve et al., 2007).
These effects are mainly mediated through classical estrogen
receptor (ER) a and ERb, which are both expressed in endothelial
cells (Sobrino et al., 2010). A third type of ER, G-protein coupled
which is primarily localized to the endoplasmic reticulum, named
GPER, mediates several rapid and non-genomic estrogen effects
(Prossnitz and Barton, 2011).
The available information on the role of ADMA in the regulation
of endothelial response to estradiol has been mainly obtained in
endothelial cells from venous origin. However, there is a lack of
data about the effects of estradiol on DDAH/ADMA/NO pathway
on arterial endothelial cells. Despite their common developmental
origins, venous and arterial endothelial cells are not identical, dif-
fering widely in morphology and function. (Chi et al., 2003; Sobrino
et al., 2009; dela Paz and D’Amore, 2009). Moreover, in the case of
endothelial cells cultured from umbilical cord, it must take into ac-
count that in the umbilical circulation, the vein carries the oxygen-
ated blood while the arteries carry the deoxygenated blood.
Thus, our aim was to study the interactions of a well known car-
diovascular risk factor oxLDL with DDAH/ADMA/NO pathway, and
the role of estradiol and ER on the observed effects in human
umbilical artery endothelial cells (HUAEC).2. Methods
2.1. Cell culture and experimental design
HUAEC were isolated from arteries from freshly human umbil-
ical cords, as previously described (Abu-Taha et al., 2009). Brieﬂy,
both umbilical arteries were isolated, cannulated, their interior
washed with PBS and then incubated 15 min with a 0.2% type II
collagenase solution (Invitrogen, Barcelona, Spain). Then, the colla-
genase solution containing the endothelial cells was sedimented,
washed twice with 199 medium (Sigma–Aldrich, Alcobendas,
Spain) containing 20% fetal bovine serum (Invitrogen). HUAEC
were then grown in gelatin-coated ﬂasks in human endothelial
cell-speciﬁc medium EBM-2 (Lonza, Basel, Switzerland) supple-
mented with EGM-2MV (Lonza) in an incubator at 37 C with 5%
CO2. Cells were identiﬁed as endothelial by their characteristic cob-
blestone morphology and the presence of von Willebrand factor by
immunocytochemistry using a speciﬁc antibody (F-3520; Sigma).
Cells in conﬂuence were exposed to 1 nM 17b-estradiol (Sigma–
Aldrich), 100 lg/mL native LDL (nLDL) or 100 lg/mL oxLDL, and
their combinations. These concentrations were chosen based on
our previous studies, and were able to modify DDAH/ADMA/NO
pathway in other types of endothelial cells (Monsalve et al., 2007).
LDL was isolated and pooled from fasting plasma samples from
healthy donors (nLDL). oxLDL was prepared by incubation with
10 lM CuSO4 (4 h at 37 C) as previously described (Monsalveet al., 2007). The effectiveness of LDL oxidation was assured by
measuring malondialdehyde levels in duplicate on the nLDL as well
as the oxLDL samples. Malondialdehyde levels (mean ± SEM of 6
values corresponding to 3 experiments) were 0.7 ± 0.1 nmol/mg
protein for nLDL and 3.6 ± 0.5 for oxLDL (p < 0.05).
In some experiments, to study the role of ER, cells were also ex-
posed to the unspeciﬁc antagonist of ERa and ERb ICI 182780
(1 lM), the speciﬁc ERa antagonist MPP (1 lM), the selective
ERa agonist PPT (10 nM), the selective ERb agonist DPN (10 nM),
or the selective GPER agonist G1 (10 nM), all of them from Tocris
Bioscience (Ellisville, MI, USA). Despite GPER receptors are de-
scribed to mediate acute cardiovascular effects in response to
estradiol (Li et al., 2012), we decided to rule out a possible interfer-
ence and included the use of G1 agonist in this study.
This investigation conforms to the principles outlined in the
Declaration of Helsinki, was approved by the Ethical Committee
of Clinical Research of the INCLIVA, Hospital Clínico of Valencia,
Spain, and written informed consent was obtained from all
donors.2.2. Isolation and measurement of dimethylarginines
After 24 h of incubation with the desired treatments, medium
was stored at 20 C until dimethylarginines quantiﬁcation and
cells were collected in 0.5 N NaOH solution for protein determina-
tion by the BCA method (Thermo Scientiﬁc Inc., Rockford, IL, USA).
Measurement of ADMA and symmetrical dimethylarginine
(SDMA) was accomplished by high-performance liquid chromatog-
raphy (HPLC) as described earlier (Hermenegildo et al., 2002).2.3. NO production
After 24 h of incubation with the desired treatments, cells were
washed and incubated with 5 mM HEPES containing (in mM) 140
NaCl, 5 KCl, 2 CaCl2, 1 MgCl2 and 10 glucose, pH adjusted to 7.4),
for 120 min. Then, incubation medium was collected and stored
at 20 C until NO measurement. Culture wells were then washed
with PBS, and adherent cells were collected in 0.5 N NaOH solution
for protein determination by the BCA method (Thermo Scientiﬁc
Inc., Rockford, IL, USA). Endothelial NO production was determined
using the ISONOP nitric oxide sensor (World Precision Instruments,
Sarasota, FL, USA) an amperometric sensor speciﬁc for NO as de-
scribed earlier (Monsalve et al., 2007).2.4. Immunoblotting
Treated HUAEC were collected in RIPA buffer (Sigma) contain-
ing protease inhibitors (complete ULTRA Tablets, Roche Diagnos-
tics, Madrid, Spain) and phosphatase inhibitors (PhosStop
Tablets, Roche Diagnostics). Protein content was measured and
samples were frozen at 20 C until assay. Equal amounts of pro-
tein were then separated by 7–12% of SDS–Polyacrylamide gel
electrophoresis. Protein was then transferred to PVDF sheets (PVDF
Transfer Membrane, Bio-Rad, Madrid, Spain). Immunostaining was
achieved using speciﬁc antibodies anti-PRMT-1 (sc-59647), anti-
DDAH-I (sc-26068), anti-DDAH-II (sc-32859), and eNOS (sc-653),
all from Santa Cruz Biotechnology Inc. (Heidelberg, Germany),
and anti-eNOS phosphorylated at Ser1177 (9571; Cell Signaling
Technology, Danvers, MA, USA). Development was performed with
horse rabbit peroxidase-linked antibodies (Sigma), followed with
Supersignal Chemiluminescent Substrate (Thermo Scientiﬁc Inc.).
Signal density was analyzed with ImageGauge 4.0 software. Equiv-
alent protein loading and transfer efﬁciency were veriﬁed by stain-
ing for b-actin (Sigma).
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A colorimetric assay was used to measure cellular DDAH activ-
ity using diacetyl monoxime derivatization of the ureido group in
L-citrulline, quantiﬁed by spectrofotometry (466 nm) as previously
described (Prescott and Jones, 1969).
Brieﬂy, cells were collected by scraping in PBS 0.1 M pH 6.5 and
lysated in several cycles of freeze and thaw. NG-monomethyl-L-
arginine (L-NMMA, Sigma) was added as substrate to a ﬁnal con-
centration of 4 mM. Cell lysates were incubated at 37 C for 2 h be-
fore the addition of 30% sulfurosalicylic acid to stop the reaction.
The L-citrulline formation was determined by the color develop-
ment at 95 C with an acid mixture of diacetylmonoxime (0.8% in
5% acetic acid) and antipirine (0.5% in 50% sulphuric acid), and read
at 466 nm. DDAH activity was expressed as percentage of control
values.
2.6. Measurement of cell viability
Cell viability was assessed as previously reported (Hermene-
gildo et al., 2005). None of the tested experimental conditions
showed a percentage of viability on HUAEC lesser than 75% (data
not shown).
2.7. Statistical analysis
Values shown in the text and ﬁgures are mean ± Standard Error
of Mean (SEM) from data obtained in 4–11 experiments. ANOVA
test was applied for comparisons of mean, and then Bonferroni’s
test was performed. P values < 0.05 were considered signiﬁcant.
The statistical analysis was carried out using the Prism 4 software
(GraphPad Software Inc., San Diego, CA, USA).
3. Results
3.1. Dimethylarginine levels
We ﬁrst checked the effect of LDL and estradiol on dimethylar-
ginine production by HUAEC. Exposition to oxLDL (100 lg/mL) for
24 h signiﬁcantly increased the concentration of ADMA by 49%
(p < 0.05 vs. control) in culture supernatant (Fig. 1A). By contrast,
nLDL (100 lg/mL) and estradiol (1 nM) administered alone or in
combination did not modify the concentration levels of dimethy-
larginines on culture supernatant. Co-exposure with oxLDL andA
Fig. 1. Estradiol reverses oxLDL-increased ADMA production. Endothelial cells were expo
for 24 h. Culture medium was then collected and (A) ADMA and (B) SDMA concentrati
control values. Each bar represents the mean ± SEM of 4 values corresponding to 4 exper
oxLDL).estradiol signiﬁcantly reduced the elevated concentration of ADMA
(79%; p < 0.05 vs. control and vs. oxLDL alone), suggesting that in
HUAEC estradiol only decreases ADMA levels when oxLDL is pres-
ent. No changes were observed in SDMA levels after the different
experimental conditions (Fig. 1B).
3.2. NO production by HUAEC
NO production was measured by an amperometric method
based in the formation of nitrites from NO. After treatment with
estradiol, nLDL and estradiol + nLDL, NO concentrations remained
unchanged. Nevertheless, oxLDL (100 lg/mL) for 24 h decreased
by 60% the amount of NO produced by HUAEC. Estradiol, in combi-
nation with oxLDL, stimulated NO production above control values
(124%) (p < 0.05) (Fig. 2). As expected, the effects of estradiol and
LDL mirrored the expected results obtained with ADMA measure-
ment: the increased ADMA production induced by oxLDL was
accompanied by a reduction in NO production, and the reduced
ADMA production induced by estradiol + oxLDL was accompanied
by an increase in NO production.
To study the involvement of ER, we exposed cells to ER antago-
nists. The increased NO production induced by estradiol + oxLDL
was completely abolished by ICI 182780, suggesting the involve-
ment of the classic ER on that effect, and by the selective ERa
antagonist MPP (p < 0.05 vs. estradiol + oxLDL), suggesting an
involvement of ERa in the restoration of NO levels induced by
estradiol in oxLDL-treated cells (Fig. 2). To further conﬁrm that
NO restoration by estradiol is only mediated by ERa, and to discard
the involvement of other ER, we studied the effect of different, spe-
ciﬁc agonists for ERa, ERb and the GPER (PPT, DPN and G1, respec-
tively; Fig. 3). The ERa agonist was able to completely restore the
NO levels decreased by oxLDL, to the same level than estradiol
(Fig. 3), whereas neither ERb nor GPER agonists modiﬁed the effect
induced by oxLDL alone.
Taken together, the effects presented in Figs. 2 and 3 demon-
strate that estradiol was able to counteract the oxLDL-reduced
NO production acting through ERa.
3.3. Protein expression
Our next step was to study whether these effects were due to a
modiﬁcation on the protein expression of the enzymes of the
DDAH/ADMA/NO pathway. Western blotting analysis were per-
formed for PRMT-1, DDAH-I, DDAH-II and eNOS proteins in HUAECB
sed to 100 lg/mL of either nLDL or oxLDL in the absence/presence of 1 nM estradiol
on was measured as described in Methods. Results are expressed as percentage of





















Estradiol (1 nM) - - - + + + - + - +
nLDL (100 µg/mL) - + - - + - - - - -
oxLDL (100 µg/mL) - - + - - + + + + +
MPP (1 µM) - - - - - - + + - -
ICI 182780 (1 µM) - - - - - - - - + +
*#*
Fig. 2. oxLDL-impaired NO production is increased by estradiol through ERa.
Endothelial cells were exposed to desired treatments for 24 h. Culture medium was
then collected and NO concentration was measured as described in Methods.
Results are expressed as percentage of control values and represents the mean ± -
SEM of 5–12 values corresponding to 9 experiments performed in cells from
different cultures (⁄p < 0.05 vs. control; ⁄⁄p < 0.01 vs. control; p < 0.05 vs. oxLDL;
#p < 0.05 vs. oxLDL + estradiol).
Fig. 3. ERa agonist selectively counteracts oxLDL-impaired NO production. Endo-
thelial cells were exposed to desired treatments for 24 h. Culture medium was then
collected and NO concentration was measured as described in Methods. Results are
expressed as percentage of control values and represents the mean ± SEM of 5–16
values corresponding to 11 experiments performed in cells from different cultures
(⁄⁄p < 0.01 vs. control; p < 0.05 vs. oxLDL).
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used as housekeeping protein (Fig. 4). The expression of PRMT-1
and DDAH-I were unaffected by any treatment (Fig. 4B and C). Con-
versely, changes in DDAH-II and eNOS expressions and eNOS phos-
phorylation in Ser1177 were observed after exposition to
treatments (Fig. 4D–F).
DDAH-II expression remained unchanged after exposure to
estradiol, was signiﬁcantly increased (p < 0.05) in HUAEC treated
with oxLDL, and remained elevated after treatmentwith oxLDL plus
estradiol (Fig. 4D). The eNOS protein expression was signiﬁcantly
reduced (p < 0.05) by oxLDL treatment, whereas estradiol was able
to completely reverse it (Fig. 4E). The activating phosphorylation of
eNOS on Ser1177, as phosphorylated eNOS to total eNOS ratio, is
presented in Fig. 4F. Estradiol increased eNOS phosphorylation on
Ser1177/total eNOS ratio. The impaired eNOS phosphorylation after
exposure to oxLDL (Fig. 4A) was related to the reduced eNOS
expression (Fig. 4E), and therefore the phosphorylation ratio re-
mained unchanged (Fig. 4F). Also, the phosphorylation ratio did
not change when cells were exposed to both treatments (Fig. 4F).
3.4. DDAH enzymatic activity
The increased DDAH-II protein levels after exposure to oxLDL
with or without estradiol did not match with ADMA levels. There-
fore, DDAH activity was investigated. Neither estradiol nor nLDLmodiﬁed DDAH activity, but was signiﬁcantly decreased to 59%
after incubation with oxLDL (p < 0.05). Interestingly, estradiol not
only reversed, but also stimulated DDAH activity when cells were
exposed along with oxLDL (p < 0.05) (Fig. 5). This increment in
DDAH activity (133%) would be responsible for the low levels of
ADMA observed after treatment with oxLDL plus estradiol
(Fig. 1). The increased DDAH activity induced by the combination
of oxLDL and estradiol was mediated through ERa, since was com-
pletely prevented in the presence of both ICI 182780 and MPP
(p < 0.05) (Fig. 5).
Therefore, changes observed in the DDAH activity (Fig. 5) would
be the responsible for the alteration on NO production induced by
oxLDL, both in the presence or in the absence of estradiol.4. Discussion
Our results show how estradiol, acting through ERa, restores
DDAH activity and NO production impaired by oxLDL in HUAEC
without affecting DDAH-II expression. The main ﬁndings are (1)
the increment in ADMA production in arterial endothelial cells
due to a diminished DDAH enzyme activity in response to oxLDL,
accompanied by an increase of DDAH-II protein content, (2) the in-
creased ADMA concentration, along with a decreased eNOS protein
expression, resulted in an impaired NO production, (3) the lack of
effect of estradiol on DDAH/ADMA/NO pathway on basal condi-
tions, and (4) the restoration by estradiol of changes induced after
oxLDL treatment through ERa.
Reduced NO is a property of endothelial dysfunction. There are
two important mechanisms for impaired NO synthesis, which have
been studied in the present work. One of them is the alteration of
eNOS phosphorylation, resulting in a modify eNOS activity, and the
other one is the accumulation of endogenous NOS inhibitors such
as ADMA.
On the one hand, a direct activation of eNOS by its phosphory-
lation on Ser1177 (Dimmeler et al., 1999) could be one of the pos-
sibilities to explain changes in NO levels. In the present study,
estradiol alone do not change NO production. Although this is
the ﬁrst report on NO measurement under estradiol stimulation
in HUAEC, in other arterial endothelial cells estradiol does not
modify NO synthesis (Stewart et al., 1999).
Estradiol slightly increases eNOS phosphorylation/total eNOS
ratio without changing the total eNOS expression, but this incre-
ment is not enough to induce a signiﬁcant rise on NO production.
A possibility to explain this discrepancy is the concomitant raise
in the inhibitory phosphorylation of eNOS on Thr495 as previously
described (Fleming et al., 2001). Also estradiol could be affecting
other sources for NO as is the case of neuronal NOS isoform, de-
scribed as a functional NO source in HUVEC (Bachetti et al., 2004).
In cells exposed to oxLDL alone, total eNOS protein was re-
duced, although its phosphorylation ratio remained unchanged,
resulting in decreased NO. Nevertheless, when cells were exposed
to estradiol + oxLDL, eNOS protein and its phosphorylation re-
mained unchanged, in spite of in that cells NO production was sig-
niﬁcantly increased. Therefore, eNOS phosphorylation does not
explain the increased NO synthesis obtained after exposure to
oxLDL and estradiol.
On the other hand, in the present study oxLDL increased levels
of ADMA in HUAEC. Physiological concentrations of estradiol sig-
niﬁcantly counteracted the increment in ADMA endothelial cell
production induced by oxLDL concomitantly with an elevation of
NO release. These results suggest that estradiol could protect cells
against oxLDL-induced damage, which may involve reduction of
ADMA level and increase in NO release.
The mechanisms of this action seem to differ from those previ-






Fig. 4. Effect of estradiol and oxLDL on PRMT/DDAH/eNOS pathway protein expression. The expression of proteins involved in dimethylarginines production and eNOS was
determined by immunoblotting in HUAEC as described in Methods. (A) Representative images showing the expression of PRMT-1, DDAH-I, DDAH-II and eNOS proteins, and
the phosphorylated form of eNOS in Ser1177 are presented. b-Actin was analyzed as control. The quantiﬁcation of (B) PRMT-1, (C) DDAH-I, (D) DDAH-II, (E) eNOS and (F)
phospho-eNOS (Ser1177)/total eNOS ratio are expressed as percentage of control values and represents the mean ± SEM of 5–7 values corresponding to 4 experiments
performed in cells from different cultures (⁄p < 0.05 vs. control).
Fig. 5. oxLDL-impaired DDAH activity is increased in presence of estradiol through
ERa. DDAH enzymatic activity was measured in HUAEC lysates as described in
Methods. Results are expressed as percentage of control values and represents the
mean ± SEM of 5–12 values corresponding to 9 experiments performed in cells from
different cultures (⁄p < 0.05 vs. control; p < 0.05 vs. oxLDL; #p < 0.05 vs.
oxLDL + estradiol).
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DDAH-II) of ADMA, but only DDAH-II is modiﬁed by exposure to
oxLDL. Contrary to expectations, the increase in DDAH-II protein
expression observed in HUAEC exposed to oxLDL came with an
increment in ADMA levels. That discrepancy was explained by
the decrease in DDAH activity revealed after oxLDL exposure. Only
in presence of estradiol, DDAH activity was restored, leading to a
decrease in ADMA concentration. DDAH-II is susceptible to be
oxidized by oxLDL which make to lose its enzymatic activity. So,despite the augmentation in DDAH-II protein expression, it be-
comes inactive, leading to an enhanced accumulation of ADMA.
Neither DDAH-I nor PRMT-1 are involved in the response of
HUAEC to oxLDL and/or estradiol. The absence of estradiol stimula-
tion on DDAH-I protein expression is in accordance with previous
studies performed in murine endothelial cells (Holden et al., 2003).
In fact, the expression of DDAH-II, but not DDAH-I, protein has
been shown to be transcriptionally regulated in endothelial cells
(Vallance and Leiper, 2004).
The other possibility to explain the increase of ADMA concen-
tration could be an increase in arginine methylation by PRMT-1, in-
stead of an impaired degradation by DDAH. ADMA and SDMA share
the synthesis pathway through PRMT-1 but differ in the degrada-
tion pathway, as SDMA is not a substrate for DDAH. Both the unal-
tered PRMT-1 expression protein proﬁle and the unaltered SDMA
levels ruled out this hypothesis. In fact, SDMA remained unaltered
when cells were exposed to the different treatments, which is in
complete agreement with previous studies performed in HUVEC
(Boger et al., 2000; Monsalve et al., 2007).
Estradiol effects on DDAH/ADMA/NO pathway are mainly med-
iated through ERa. The use of competitive antagonist of ERa and
ERb, ICI 182780, and the selective ERa antagonist, MPP, completely
prevented the effect of estradiol on oxLDL-reduced NO production
and DDAH activity. By other side, the use of speciﬁc agonists for
ERa, ERb and GPER clearly suggest that ERa activation reverses
the oxLDL-impaired NO production. Taken together, these results
demonstrate a selective involvement of ERa in the reversal effect
of estradiol to the oxLDL-induced changes in DDAH/ADMA/NO
pathway in HUAEC. These results reinforce the central role of
ERa on the beneﬁcial effects exerted by estrogens on the endothe-
lial physiology (Sobrino et al., 2010; Chalopin et al., 2010). The
absence of GPER agonist effects on genomic actions is in accor-
dance to previous reports in which GPER receptors are described
16 S. Novella et al. /Molecular and Cellular Endocrinology 365 (2013) 11–16to mediate acute cardiovascular effects in response to estradiol (Li
et al., 2012).
These effects of estradiol in HUAEC were different from that
previously published in HUVEC (Holden et al., 2003; Monsalve
et al., 2007; Sobrino et al., 2009). In spite of HUVEC are often used
to study endothelial mechanisms, experiments were developed in
HUAEC in an attempt to determine if those genetic differences
could alter the response to estradiol and to atherogenic com-
pounds like oxLDL. Despite their common developmental origins,
endothelial cells are not identical, differing widely in morphology
and function, and existing different genes expressed speciﬁcally
by the endothelium of arteries (Chi et al., 2003). Fetal circulation
is rather different from adult as gas exchange does not occur in
the lungs but in the placenta. In spite of umbilical arteries carry
deoxygenated blood at relatively low blood pressure, some evi-
dences have shown that the speciﬁcation of arterial and venous
identity is largely genetically determined (dela Paz and D’Amore,
2009). In fact, phylogenetic approaches show the identity of umbil-
ical arteries to different arteries in the body and the same occurs
with veins (Chi et al., 2003).
Estradiol has also been related to ADMA levels in women. For
instance, plasmatic ADMA concentrations are lower before than
after menopause, suggesting an effect of estrogens in ADMA
metabolism (Schulze et al., 2005). Indeed, in some studies, hor-
mone replacement therapy signiﬁcantly reduced plasma concen-
trations of the cardiovascular risk factor ADMA in healthy
postmenopausal women (Post et al., 2003) and raised levels of
NO (Saitta et al., 2001) which could lead to an increase in endothe-
lium-dependent ﬂow-mediated dilation observed during oral hor-
mone replacement therapy (Vehkavaara et al., 2000).5. Conclusions
Estradiol restores the DDAH enzymatic activity affected by
oxLDL through ERa, without affecting the expression of proteins
involved in ADMAmetabolism, DDAH-I, DDAH-II and PRMT-1. This
effect decreases the accumulation of ADMA and restores NO pro-
duction. The results differ from those registered in HUVEC (Mons-
alve et al., 2007; Peng et al., 2011) indicating differences in
regulation of protein expression by oxLDL and estradiol between
arterial and venous endothelial cells.
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